Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Humacyte Inc
HUMA | US
0.65
USD0.04
6.33%
HUMA | US
About Humacyte Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
0.65
Open
0.61
High
0.67
Low
0.60
Humacyte Inc. engages in the development and manufacture of off-the-shelf implantable and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs which would target the vascular repair reconstruction and replacement market including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham North Carolina.
View LessHUMA | US
Risk
124.2
Sharpe
-0.44
Luna's Score
31/100
Recommendation
Sell
Luna says (HUMA | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
137.2%1 month
124.2%3 months
120.9%6 months
101.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
30.28
Debt to equity
-0.63
Debt to assets
0.13
Ent. to EBITDA
4.34
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-99.65M
MarketCap
80.88M
MarketCap(USD)
80.88M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-850.81
Short ratio
6.28
Short perc.
17.65
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.22
Range1M
0.71
Range3M
0.76
Volumes: Market Activity
Rel. volume
0.48
Price X volume
2.99M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 4.34 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 30.28 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 120.88 | - | Riskier |
| Debt to Equity | -0.63 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 80.88M | - | Emerging |
